MAR 20, 2019 11:39 AM PDT

First Drug for Postpartum Depression

WRITTEN BY: Nouran Amin

The U.S. Food and Drug Administration recently approved the first ever drug specifically for the treatment of postpartum depression--a common and often devastating condition for new mothers which interferes with the maternal-infant bond. The approval of the drug came after the success of two clinical trials."Postpartum depression is a serious condition that, when severe, can be life-threatening," noted the FDA's Dr. Tiffany Farchione, who is acting director of the Division of Psychiatry Products in the agency's Center for Drug Evaluation and Research. "Women may experience thoughts about harming themselves or harming their child."

The drug is called Zulesso (brexanolone) and would be delivered intravenously.

"There is tremendous stigma around postpartum depression for women. Many women experience great shame and feel inadequate as mothers if they struggle with depression at a time that is supposed to be joyous ," says Dr. Martha Wald, a psychiatrist and psychoanalyst at Duke University, in Winston-Salem, N.C. "Because of this stigma, many women choose to not seek help and endure great suffering in silence," she said. "Postpartum depression affects 15 to 20 percent of the general population, and at least half of this group goes untreated. As more targeted treatments like this become available, more mothers are likely to seek and benefit from treatment."

Zulesso is different than any other antidepressant as it specifically acts on the main inhibitory neurotransmitter system of the brain, the GABA system. The drug also cocnatins an aturally occurring steroid in the body—allopregnanolone. "Allopregnanolone is known to modulate the stress response system in humans, which has been shown to be abnormally functioning in women with postpartum depression," explained Dr. Kristina Deligiannidis, the lead investigator on the clinical trials that led to Zulesso's approval.

Source: MedicalXpress.com

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JAN 07, 2019
Cell & Molecular Biology
JAN 07, 2019
Researchers Develop an Experimental Therapy for Triple-negative Breast Cancer
Between 12 and 17% of all breast cancer cases are triple-negative, a highly aggressive type with few therapeutic options....
FEB 17, 2019
Drug Discovery
FEB 17, 2019
Drug Combination May Become Standard Treatment for Metastatic Kidney Cancer
Reporting from results of a phase 3 clinical trial, patients with metastatic kidney cancer may soon receive a new standard treatment involving a combinatio...
FEB 17, 2019
Drug Discovery
FEB 17, 2019
Dangers of an OTC Diarrhea Medication
A recent study by Rutgers University found that overdosing on loperamide—a non-prescription, over-the-counter diarrhea medication, has increased nati...
FEB 24, 2019
Drug Discovery
FEB 24, 2019
Possible Therapeutic for Duchenne Muscular Dystrophy (DMD)
Individuals diagnosed with Duchenne muscular dystrophy (DMD) face few treatment options. DMD is a progressive muscle weakness and degeneration with loss of...
FEB 25, 2019
Drug Discovery
FEB 25, 2019
Open-Science Model Advances Drug Discovery
Parkinson’s disease and Amyotrophic Lateral Sclerosis is the latest push for Medicines 4 Neurodegenerative Diseases (M4ND Pharma) by academic scienti...
APR 20, 2019
Drug Discovery
APR 20, 2019
The Microfluidic-Based Drug Screening Chip
A team of researchers, at the Korea Advanced Institute of Science and Technology (KAIST), created a high throughput microfluidic-based drug screening chip ...
Loading Comments...